CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Cilta-cel：一种靶向 BCMA 的 CAR-T 疗法，用于重度经治的复发/难治性多发性骨髓瘤患者
英文原题：Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
查看英文原题
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Cilta-cel是一种靶向BCMA的CAR-T 细胞疗法，用于治疗多发性骨髓瘤，于2022年2月28日在美国获批，用于既往接受过4线治疗（包括蛋白酶体抑制剂、免疫调节药物和抗CD38单克隆抗体）的复发/难治性疾病患者。随后在欧盟获批，用于既往接受过3线治疗的患者。在中位28个月随访时，关键性CARTITUDE-1试验显示缓解率为98%（83%为严格完全缓解）；中位无进展生存期尚未达到，不良事件可通过支持治疗进行管理。Cilta-cel在更早期治疗线中的疗效和安全性，以及其在复杂治疗格局中的最佳排序，是重要的研究领域。
展开英文摘要原文
Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Approval in the EU followed for patients with 3 prior therapies.
At median 28-month follow-up, the pivotal CARTITUDE-1 trial showed a 98% response rate (83% stringent complete response); median progression-free survival had not been reached, and adverse events could be managed with supportive therapy. Cilta-cel efficacy and safety in earlier lines of therapy, and its optimal sequencing in a complex treatment landscape are important areas of investigation.
论文信息
- 作者
- Martin TG、Madduri D、Pacaud L、Usmani SZ
- 第一作者单位
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.United States
- 通讯作者单位
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.United States
- 文献类型
- 综述
- 期刊
- Future oncology (London, England)2023 Nov
- 原文标识
- PubMed 37497629 · DOI 10.2217/fon-2022-1317